Hi, KMP. Jot your question down exactly as you'd like it asked. I'll make a list. I'm sleepy. I'm going to do some brainstorming here. Add to this rough draft. And I'll add to this list as well over the week as I think of something relevant.
And Whatsup, you can make a contribution too. If you can ask a question here in writing rather than act inappropriately in our conference call, I'd prefer you do that here. And then I'll edit it and make it polite, without changing your meaning. Scouts honor!
And Steady Kicker, if you can -- Well, just do whatever it is you do. Just try not to talk unless absolutely necessary. Grunt if you have to, but just try to focus on the food. Keep it simple.
1) A year or so ago, there was mention of dual listing on the Sedar exchange. Can you explain why that plan was dropped, and do you have any plans to do that in the future?
2) In the last conference call, you said, "We're already seeing substantially improved offerings of finance that we hope to report positively on in the Q2 call." Would you be able to elaborate on that some?
3) Between July and August, there were 500,000 extra shares added to the OS. I feel like they were from conversions. It hurts to see. I worry about excessive dilution at these prices, but what's is your thoughts on that? Am I look at it wrong, and how do you see the future in terms of that.
4) Would it be fair to say that Mj Freeway and BioTrack are direct competitors? Do you see it that way? And if so, do they win contracts because of lower pricing? It seems to me that their margins are lower, and I'm wondering if that's because they are undercutting you in price. Am I understanding that correctly? Their stock is higher than ours, and I'm wondering what your thoughts are on the reasons behind that.
